Stay up to date on the latest Foundation news and research.

Join Today!
  • Skip to main content
  • Skip to footer
Foundation Fighting Blindness homepage
Search
My Chapter:
View Chapter
Donate
  • Understanding Vision Loss
    • Vision Loss Glossary
    • Retinal Education Videos
    • Achromatopsia
    • Bardet-Biedl Syndrome (BBS)
    • Best Disease
    • Choroideremia
    • CRB1-Associated Diseases
    • Geographic Atrophy (GA)
    • Leber Congenital Amaurosis (LCA)
    • Macular Degeneration
    • PRPH2-Associated Diseases
    • Retinitis Pigmentosa
    • Refsum Disease
    • Stargardt Disease
    • Thyroid Eye Disease
    • Usher Syndrome
    • X-Linked Retinoschisis (XLRS)
    • Rare Retinal Conditions
  • Living With Vision Loss
    • Information for the Newly Diagnosed
    • Mental Health Resource Center
    • Beacon Stories
    • Low Vision Resources
    • Retinal Doctors Directory
    • Accessibility Guidelines and Virtual Meeting Tips
  • Research
    • Science Strategic Plan
    • My Retina Tracker Program
    • Clinical Trials
    • Clinical Trial Pipeline
    • Grants &
Awards
    • Funded Projects
    • Eye Donor Program
    • Continuing Education
  • Get Involved
    • Join a Chapter
    • Register for VisionWalk
    • Donate Today
    • Host a Fundraiser
    • Legacy Giving
    • Shop to Support
    • Partner with Us
  • News
    • News
    • Foundation News
    • Podcasts
    • Find Foundation Podcasts
    • Music to Our Eyes Videos
    • In Focus Newsletter
    • Legacy Newsletter
    • For Media
    • RSS Feeds
    • Sign Up for Alerts
  • Events
    • Upcoming Events
    • VisionWalk
    • Insights Forum
    • VISIONS Conference
    • Awareness Calendar
  • Genetic Testing Program
  • For Eye Care Professionals
  • About
    • Mission & History
    • Board of Directors
    • Leadership
    • Strategic Council
    • Scientific Advisory Board
    • National Trustees
    • Corporate Partners
    • Financials & Governance
    • Annual Reports
    • Careers
    • Contact
  • Ways to Give
    • Credit Card, ACH & PayPal
    • Legacy Giving
    • Donor Advised Funds
    • Stock Donations
    • Crypto Donations
    • Join a VisionWalk
    • Host a Fundraiser
    • Corporate Partnerships
Change colorTheme
Science Strategic Plan

Strategic Plan Details

  • Email
  • Share on Facebook
  • X Tweet

Jump to Section

  • Comprehensive Research Portfolio Overview
  • Strategy 1: Drive research that establishes clinically meaningful IRD endpoints.
  • Strategy 2: Drive research for late-stage disease therapies.
  • Strategy 3: Drive research to mitigate immunological triggers in disease and treatments.
  • Strategy 4: Drive research that explores and understands IRD genes and variants across diverse populations.
  • Strategy 5: Drive research to develop better models of IRD and AMD diseases.
  • Strategy 6: Drive research for specific, targeted disease-causing genes.

Comprehensive Research Portfolio

After a review by our Scientific Advisory Board (SAB), three key research gaps were identified: models to study retinal diseases, understanding how the immune system reacts, and finding biomarkers that can predict disease progression and help guide treatment decisions. A fourth gap, highlighted by our genetics team, focuses on improving diversity in research to create more inclusive treatment options for everyone.

Strategy 1: Drive research that establishes clinically meaningful IRD endpoints.

A major gap continues to be the lack of global alignment between patients, industry, and regulators on meaningful endpoints for IRD and dry AMD clinical trials.  Specifically, we lack endpoints that connect functional and structural vision changes over time and in response to therapeutics. The challenges result from our target patient populations in relevant clinical trials may exhibit highly variable phenotypes, disease progression rates, and phenotype-genotype correlations between and among groups. Our priority is to fund research and clinical studies in this area that include leveraging clinical activity within the RD Fund portfolio.

Strategy 2: Drive research for late-stage disease therapies.

Emerging treatments for inherited retinal disease using gene replacement and gene editing, as well as small molecule therapies to slow disease progression, do not benefit individuals with severe vision loss in the late stage of disease.  Our priority is to fund research to advance therapies for patients in this subpopulation. For example, it is notable that the median age of MRTR patients affected with an IRD is 56 years.

Strategy 3: Drive research to mitigate immunological triggers in disease and treatments.

There have been advances in understanding the immune response to gene therapy vehicles, but ways to combat inflammation when it surfaces post treatment with cell and gene therapy approaches are limited. Our priority is to fund research and development in this area.

Strategy 4: Drive research that explores and understands IRD genes and variants across diverse populations.

The predominant inclusion of individuals from mostly European ancestry in IRD gene identification efforts has limited the utility of IRD gene panels for individuals from non-European ancestry.  Our priority is to fund research and development of tools in this area.

Strategy 5: Drive research to develop better models of IRD and AMD diseases.

The lack of cellular and/or animal models that accurately reflect human disease pathology remains a critical gap for the translation of preclinical studies to humans. Our priority is to fund research and development in this area.

Strategy 6: Drive research for specific, targeted disease-causing genes.

chevron-thin-up scroll to top
Foundation Fighting Blindness homepage

The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.

NORD 2025 Platinum Member Charity Watch Top Rated GuideStar 2020 Platinum Seal of Transparency GuideStar 2020 Platinum Seal of Transparency Better Business Bureau Accredited Charity Charity Navigator WCAG 2.1 compliant, level double A

The Foundation Fighting Blindness meets all 20 Better Business Bureau Charity Standards.

Stay connected by receiving updates and communications from the Foundation!

Sign Up

Get in Touch

  • Facebook.
  • Twitter. X
  • YouTube.
  • Instagram.
  • Linkedin. linkedin
  • Tiktok. tiktok

Foundation Fighting Blindness

Phone: (800) 683-5555

6925 Oakland Mills Road, #701, Columbia, MD 21045.

Donations can be mailed directly to:
Foundation Fighting Blindness, P.O. Box 45740, Baltimore, MD 21297-5740

  • Contact
  • Careers
  • For Media
  • Accessibility
  • Privacy Policy
  • Site Map

© 2025 Foundation Fighting Blindness, All Rights Reserved. The Foundation Fighting Blindness is a qualified 501(c)(3) non-profit organization and all donations are tax deductible. EIN 23-7135845.